Kiora's KIO-301 shows vision improvement in blind RP patients in Phase I/II trial

KIORA PHARMACEUTICALS INC

Visual field increased significantly (p<0.05) at days 7 and 14; high-dose group gained 0.30 logMAR (3 lines) visual acuity.
Functional MRI showed increased brain activity in visual cortex; mobility test improvement from 24.7% to 60.0% at day 28.
No serious adverse events or retinal inflammation; duration of effect supports monthly IVT injection.
Company plans sham-controlled Phase II trial in 2024; will share ABACUS results with FDA in Q4 2023.
Patients with no light perception regained ability to perceive light; Odds Ratio 2.1-4.2 for light perception improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.